

# Carbonic Anhydrase 9 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/C011DC610E49EN.html>

Date: December 2019

Pages: 50

Price: US\$ 3,500.00 (Single User License)

ID: C011DC610E49EN

## Abstracts

Carbonic Anhydrase 9 - Pipeline Review, H2 2019

### SUMMARY

According to the recently published report 'Carbonic Anhydrase 9 - Pipeline Review, H2 2019'; Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) pipeline Target constitutes close to 11 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Carbonic anhydrase 9 (CA9/CAIX) is an enzyme encoded by the CA9 gene. CA IX is a transmembrane protein and is one of only two tumor-associated carbonic anhydrase isoenzymes. It is expressed in all clear-cell renal cell carcinoma, but is not detected in normal kidney or most other normal tissues. It participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid.

The report 'Carbonic Anhydrase 9 - Pipeline Review, H2 2019' outlays comprehensive information on the Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Carbonic Anhydrase 9 (Carbonate Dehydratase

IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Oncology and Central Nervous System which include indications Breast Cancer, Endometrial Cancer, Glioblastoma Multiforme (GBM), Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Peripheral Neuropathy (Sensory Neuropathy), Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM) and Solid Tumor.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1)

The report reviews Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma

Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Overview

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Companies Involved in Therapeutics Development

Akshaya Bio Inc

EstryX Pharma Ltd

Kalgene Pharmaceuticals Inc

SignalChem Lifesciences Corp

Telix Pharmaceuticals Ltd

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Drug Profiles

(acetazolamide + temozolomide) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ESE-15-ol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLC-0111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLC-149 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CA9 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Carbonic Anhydrase IX for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Carbonic Anhydrase IX for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma -  
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STX-140 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TX-250 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CA9 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN

or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) -  
Dormant Products

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN  
or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) -  
Product Development Milestones

Featured News & Press Releases

Aug 30, 2019: Telix Pharmaceuticals to launch Japanese Renal Cancer Imaging Study

Aug 20, 2019: First Australian patient dosed in ZIRCON phase III trial

Jul 19, 2019: Telix Pharmaceuticals: Japanese regulatory update for renal cancer  
imaging program

Jul 15, 2019: Telix Pharmaceuticals reports positive phase III meeting with the FDA

Jun 13, 2019: Telix Pharmaceuticals and Eczacibasi-Monrol sign manufacturing and  
distribution agreement

Jun 05, 2019: Heidelberg Pharma receives milestone payment from partner Telix

Mar 20, 2019: cGMP manufacturing of TLX250 complete

Oct 23, 2018: Telix commences ZIRCON phase III renal cancer imaging trial

Oct 17, 2018: Telix Selects RTM to Manufacture Kidney Imaging Program in Europe

Oct 15, 2018: Interim analysis of 89 Zr-TLX250-CDx bridging study ("ZIR - DOSE")  
demonstrates significantly improved patient dosimetry

Oct 15, 2018: Telix and Cyclotek Enter into Manufacturing Partnership for Kidney  
Cancer Imaging

Aug 23, 2018: Heidelberg Pharma: Partner Telix Pharmaceuticals Files Phase III Trial  
for Kidney Cancer Imaging in Europe

Jul 26, 2018: Telix Pharmaceuticals and JFE Progress japanese manufacturing  
partnership

Jun 25, 2018: Telix and Isologic conclude manufacturing agreement for North America

May 02, 2018: Telix Pharmaceuticals Selects Goodwin Biotechnology as Manufacturing  
Scale-up Partner

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Indication, H2 2019  
Number of Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019  
Number of Products under Investigation by Universities/Institutes, H2 2019  
Products under Investigation by Universities/Institutes, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Pipeline by Akshaya Bio Inc, H2 2019  
Pipeline by EstryX Pharma Ltd, H2 2019  
Pipeline by Kalgene Pharmaceuticals Inc, H2 2019  
Pipeline by SignalChem Lifesciences Corp, H2 2019  
Pipeline by Telix Pharmaceuticals Ltd, H2 2019  
Dormant Projects, H2 2019



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

Akshaya Bio Inc

EstryX Pharma Ltd

Kalgene Pharmaceuticals Inc

SignalChem Lifesciences Corp

Telix Pharmaceuticals Ltd

## I would like to order

Product name: Carbonic Anhydrase 9 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/C011DC610E49EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C011DC610E49EN.html>